Propanc Biopharma, Inc.
PPCB
$1.86
-$0.09-4.62%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -54.07M | -430.20K | -354.30K | -358.60K | -526.70K |
| Total Depreciation and Amortization | 5.10K | 4.30K | 5.50K | 5.80K | 4.80K |
| Total Amortization of Deferred Charges | 59.60K | 76.70K | 57.00K | 47.40K | 81.70K |
| Total Other Non-Cash Items | 53.67M | 107.40K | -12.70K | 149.60K | 600.00 |
| Change in Net Operating Assets | 192.80K | 235.50K | 68.90K | -104.20K | 336.90K |
| Cash from Operations | -136.20K | -6.30K | -235.50K | -260.00K | -102.80K |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | 195.50K | 178.20K | 215.70K | 239.00K | 55.60K |
| Total Debt Repaid | -8.00K | -98.40K | -- | 0.00 | 0.00 |
| Issuance of Common Stock | -- | -- | -- | 12.00K | 11.10K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 187.50K | 79.80K | 215.70K | 251.00K | 66.60K |
| Foreign Exchange rate Adjustments | -15.20K | -68.20K | 8.00K | 23.90K | -29.30K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 36.10K | 5.40K | -11.80K | 14.90K | -65.40K |